Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25997174 | 0.99 | LTB4R (0.47) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL25997188 | 0.99 | LTB4R (0.47) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL26062065 | 0.99 | LTB4R (0.47) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL26062052 | 0.99 | LTB4R (0.47) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL26062041 | 0.94 | LTB4R (0.41) | LTB4RPPARATBXAS1CYP1A2CYP2C9 | |
| SCHEMBL22921383 | 0.91 | LTB4R (0.46) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL25997167 | 0.91 | LTB4R (0.36) | LTB4R | |
| SCHEMBL22921369 | 0.90 | LTB4R (0.48) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL22921322 | 0.90 | LTB4R (0.48) | LTB4RPPARATBXAS1ACLYCYP1A2 | |
| SCHEMBL22921417 | 0.90 | LTB4R (0.48) | LTB4RPPARATBXAS1ACLYCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | LTB4R 854/4885PPARA 99/4885TBXAS1 3787/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | LTB4R 1119/4885PPARA 8/4885TBXAS1 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.